IMMUNOPRECISE ANTIBODIES LTD.

Inactive Instrument

Highlights ImmunoPrecise Antibodies Ltd. Toronto S.E.

Equities

IPA

CA45257F2008

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform	Apr. 22	CI
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments	Apr. 12	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 14	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 14	CI
Jobs Data in Focus as Exchange-Traded Funds, Equity Futures Lean Higher Pre-Bell Wednesday	Dec. 06	MT
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology	23-10-20	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-14	CI
ImmunoPrecise Antibodies Ltd. Announces Board Changes	23-09-06	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Full Year Ended April 30, 2023	23-07-10	CI
ImmunoPrecise Antibodies Ltd. Introduces Transformative AI-Driven Rapid Therapeutic Screening Platform	23-06-06	CI
ImmunoPrecise Enters Into Research Collaboration, License Option Agreement With Xyphos Biosciences	23-03-30	MT
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas	23-03-30	CI
ImmunoPrecise Antibodies Ltd. Announces European Patent Office to Grant Biokey’S Patent Application for Foundational HYFT® Technology	23-03-27	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	22-12-15	CI
IPA Subsidiary BioStrand, BriaCell in AI Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies	22-11-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer